Advancing the Future of Neurodegenerative Disease Together
Kivara Neurosciences collaborates with pharmaceutical companies, academic institutions, healthcare systems, diagnostic laboratories, and research organizations to accelerate the development, validation, and clinical adoption of next-generation molecular diagnostics for Alzheimer’s disease and other neurodegenerative disorders.
Building the Next Generation of Precision Neurology
Six core capabilities that make Kivara a distinctive scientific partner for organizations advancing earlier detection of neurodegenerative disease.
Proprietary InterceptIQ™ Platform
A purpose-built molecular diagnostics platform engineered for neurodegenerative disease.
Multi-Omic Biomarker Integration
Genomic, proteomic, metabolic, and inflammatory signals analyzed together.
Cell-Free DNA Expertise
Deep experience in plasma-derived cfDNA isolation, ddPCR, and fragment-level analytics.
Alzheimer's Biomarker Development
Active programs focused on p-tau217 and next-generation Alzheimer's biomarkers.
Precision Diagnostics
Clinical-grade laboratory operations and assay validation experience.
Translational Clinical Research
A research-first culture that bridges molecular biology and clinical practice.
Multiple Ways to Collaborate
From therapeutic development to clinical implementation, Kivara offers flexible partnership models tailored to each collaborator’s scientific and strategic priorities.
Accelerating Therapeutic Development
Kivara supports therapeutic developers across the discovery, clinical, and commercial lifecycle with molecular tools designed for neurodegenerative disease.
- Companion diagnostics
- Patient stratification
- Clinical trial enrollment
- Pharmacodynamic biomarkers
- Treatment response monitoring
- Disease progression biomarkers
- Drug development support
- Precision medicine initiatives
Supporting Clinical Research
Kivara serves as a scientific and laboratory partner for clinical trials advancing therapies and diagnostics in Alzheimer's and other neurodegenerative diseases.
- Biomarker testing
- Baseline patient characterization
- Longitudinal molecular monitoring
- Clinical endpoint development
- Multi-site trial support
- Central laboratory services
- Research assay development
Advancing Scientific Discovery
We collaborate with academic investigators and institutions on translational neuroscience, biomarker discovery, and joint scholarship.
- Investigator-initiated studies
- Translational neuroscience
- Biomarker discovery
- Multi-omic research
- Joint grant applications
- Publication collaborations
- Fellowship programs
- Institutional partnerships
Unlock Existing Biospecimen Collections
We work with biobanks and longitudinal cohorts to retrospectively evaluate samples and uncover novel neurodegenerative signals.
- Retrospective validation
- Longitudinal cohorts
- Archived plasma studies
- cfDNA evaluation
- Neurodegenerative biomarker discovery
- AI model development
- Multi-center validation
Expanding Precision Diagnostics
Kivara partners with reference laboratories and clinical labs to broaden the reach of precision neurology testing.
- Laboratory implementation
- Technology transfer
- Clinical validation
- LDT development
- International laboratory deployment
- Reference laboratory partnerships
Earlier Detection Through Clinical Integration
We collaborate with health systems, memory clinics, and neurology programs to translate molecular insight into routine clinical care.
- Memory clinics
- Neurology practices
- Alzheimer's Centers of Excellence
- Population screening
- High-risk patient programs
- Longitudinal monitoring
- Clinical implementation research
Building Predictive Neurology
Kivara collaborates with AI and data-science groups to integrate multi-marker signals into predictive, clinically actionable models.
- Artificial intelligence
- Machine learning
- Multi-marker integration
- Predictive modeling
- Digital biomarkers
- Clinical decision support
- Bioinformatics
A Connected Ecosystem for Precision Neurology
The InterceptIQ™ Platform sits at the center of a collaborative network of clinical, academic, industrial, and international partners.
A precision molecular diagnostics platform connecting investigators, clinicians, and partners across the neurodegenerative disease ecosystem.
A Clear Path From First Meeting to Clinical Translation
An exploratory conversation between Kivara's scientific team and the prospective partner to align on shared interests and priorities.
A structured review of the scientific question, sample requirements, regulatory considerations, and program fit.
Joint development of study design, assay selection, endpoints, and analytical plan.
Execution of an appropriate agreement framework — MTA, MSA, sponsored research, or strategic collaboration.
Activation of the laboratory workflow, study logistics, and cross-team operational cadence.
Sample processing, molecular analysis, and quality-controlled data generation across the InterceptIQ™ platform.
Integrated multi-omic interpretation by scientific and bioinformatics teams in collaboration with the partner.
Joint scientific output, manuscript preparation, and translation into clinical or programmatic use.
Where We Are Building Today
Alzheimer's Disease
- Early molecular detection
- Disease progression
- Longitudinal monitoring
Parkinson's Disease
- Future pipeline
- Biomarker discovery
Multiple Sclerosis
- Emerging biomarker development
- Future expansion
Precision Neurology Platform
- InterceptIQ™
- Multi-omic diagnostics
- AI integration
Why Organizations Partner with Kivara
A Collaborative Ecosystem
Click any organization type to explore collaboration opportunities.
Let’s Advance Earlier Detection Together
Whether you’re developing therapeutics, conducting clinical research, managing a biobank, or advancing precision neurology, Kivara Neurosciences is seeking strategic collaborators to help transform the future of neurodegenerative disease detection.